



Issue of Shares

October 3, 2023

RNS Number : 56600

Renalytix PLC

03 October 2023

Renalytix plc
("Renalytix" or the "Company")

Issue of Shares

LONDON and SALT LAKE CITY, October 3, 2023 -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that under the Company's Employee Share Purchase Plan (the "ESPP"), 75,328 new ordinary shares of £0.0025 each in the capital of the Company (the "Ordinary Shares") have been issued to settle the purchase of 37,664 American Depositary Shares, each representing two Ordinary Shares, by employees who participated in the ESPP. This was carried out at a subscription price of \$2.4735 per American Depositary Share (£1.02 per Ordinary Share). Details in relation to the ESPP were contained in the Company's announcement of 2 September 2020.

An application has been made to the London Stock Exchange for the new Ordinary Shares to be admitted to trading on AIM. It is expected that admission of the 75,328 new Ordinary Shares to trading on AIM will become effective on, or around, 8am UK time on 6 October 2023 ("Admission"). The new Ordinary Shares will rank pari passu with the existing Ordinary Shares of the Company.

Total voting rights

Following Admission, the Company will have 95,094,768 Ordinary Shares in issue with each share carrying the right to one vote. The Company has no Ordinary Shares held in treasury. The total number of voting rights in the Company following Admission will therefore be 95,094,768.

For further information, please contact:

Renalytix plc
James McCullough, CEO

www.renalytix.com
Via Walbrook PR

Stifel (Nominated Adviser, Joint Broker)
Alex Price / Nicholas Moore / Nick Harland / Samira Essebiyea

Tel: 020 7710 7600

Investec Bank plc (Joint Broker)
Gary Clarence / Shalin Bhamra

Tel: 020 7597 4000

Walbrook PR Limited
Paul McManus / Lianne Applegarth/Alice Woodings

Tel: 020 7933 8780 or renalytix@walbrookpr.com
Mob: 07980541893 / 07584391303/ 07407804654

CapComm Partners
Peter DeNardo

Tel: 415-389-6400 or investors@renalytix.com

About Renalytix

Renalytix (NASDAQ: RNLX) (LSE: RENX) is an in-vitro diagnostics and laboratory services company that is the global founder

and leader in the new field of bioprognosis™ for kidney health. The leadership team, with a combined 200+ years of healthcare and in-vitro diagnostic experience, has designed its KidneyIntelX laboratory developed test to enable risk assessment for rapid progressive decline in kidney function in adult patients with T2D and early CKD (stages 1-3). We believe that by understanding how disease will progress, patients and providers can take action early to improve outcomes and reduce overall health system costs. For more information, visit www.renalytix.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lse.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

IOEEALEDEEXDFFA